47 / 112
45
WFSBP 2015
Tuesday, 16 June 2015
|
Scientific Programme
T32: P
harmacology
S-27
Symposium
15:00–16:30
Mitropoulos Hall
Therapeutic drug monitoring, pharmacogenetics and
brain imaging methods as tools for improving pharma-
cotherapy
Chair:
Christoph Hiemke, Germany
Co-Chair: Chin Bin Eap, Switzerland
S-27-001
Pharmacogenetics for improving pharmacotherapies
Chin Bin Eap, Switzerland
S-27-002
Therapeutic drug monitoring for improving pharmaco-
therapies
Christoph Hiemke, Germany
S-27-003
Brain imaging technologies in psychiatry
Gerhardt Gründer, Germany
S-27-004
Tools for improving pharmacotherapy in psychiatry:
The opinion of a clinician
Andreas Conca, Germany
T20: M
olecular
N
eurobiology
S-28
Symposium
15:00–16:30
MC 3 Room
Glutamatergic mechanisms in schizophrenia: From ket-
amine to genetic models
Chair:
Peter Gass, Germany
Co-Chair: Kazutoshi Nakazawa, USA
S-28-001
Ketamine reversal: Towards empirical discovery of antip-
sychotics with neuroimaging
Philip Corlett, USA
S-28-002
Expression analysis of a NMDA MK-801 rat model identifies
novel candidate genes for schizophrenia
Dan Rujescu, Germany
S-28-003
Mechanisms of neuronal synchrony deficits in NMDAR-hy-
pofunction-mediated schizophrenia mouse model
Kazutoshi Nakazawa, USA
K. Nakao
S-28-004
Inducible genetic mouse models to study the onset of
schizophrenia during late adolescence
Dragos Inta, Germany
H. Elkin, P. Gass
T40: S
chizophrenia
: B
asic
/ C
linical
S-29
Symposium
15:00–16:30
MC 2 Room
Alpha4beta2-nicotinic acetylcholine receptors in schiz-
ophrenia: Implications for smoking cessation and ther-
apeutics
Chair:
Deepak Cyril D‘Souza, France
Co-Chair: Eden Evins, USA
S-29-001
Nicotine dependence treatment in schizophrenia: Evidence
for effectiveness of maintenance pharmacotherapy
Eden Evins, USA
S-29-002
Neuroscience of nicotine addiction vulnerability in schizo
phrenia
Andrew Chambers, USA
S-29-003
In vivo evidence for beta2-nAChR upregulation in smokers
with schizophrenia
Deepak Cyril D‘Souza, France
I. Esterlis, M. Ranganathan, F. Bois, B. Pittman, M. Picciotto,
L. Shearer, A. Anticevic, J. Carlson, M. Niciu, K. Cosgrove
S-29-004
Nicotinic CHRNA4 genotype predicts clinical outcome in
schizophrenia and neuroleptic drug treatment response
Georg Winterer, Germany
T9: D
ementia
: B
asic
/ C
linical
S-30
Symposium
15:00–16:30
Kokkali Room
Clinical neurochemistry in the early diagnosis of demen-
tia disorders
Chair:
Piotr Lewczuk, Germany
Co-Chair: Henrik Zetterberg, Sweden
S-30-001
Current status and new developments for Alzheimer‘s
disease biomarkers
Kaj Blennow, Sweden
S-30-002
Diagnostic approaches in frontotemporal lobar degener-
ation (FTLD)
Markus Otto, Germany
S-30-003
Biomarkers for the diagnosis and progression of motor and
premotor Parkinson‘s disease
Brit Mollenhauer, Germany
S-30-004
Blood biomarkers for neurodegenerative disorders–feasible
or too much of a challenge?
Henrik Zetterberg, Sweden